Company News

  • Reset
GOLDEN, Colo. — March 1, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that their poster will be presented on March 1-3, 2022 at the Vaccination Acceptance Research Network (VARN) conference, sponsored by the Sabin Vaccine Institute. The
Tags: Polio, Tropis
Read more
GOLDEN, Colo. — February 15, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that their partner, Technovalia, has reported interim safety results from their needle-free SARS-CoV2 DNA vaccine phase 1 trial. Interim safety data of COVIGEN,
Read more
GOLDEN, Colo. — February 1, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that Chris Cappello, President and CEO of PharmaJet was featured in CEOCFO Magazine.
Read more
GOLDEN, Colo. — January 18, 2022 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Needle-free Injection System (NFIS) will be used in a clinical trial to deliver a booster vaccine against COVID-19 virus variants. The vaccine developed by DIOSynVax, a spinoff company supported by the
Read more
GOLDEN, Colo. — January 4, 2022 - PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its partner Zydus Cadila, is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine (ZyCoV-D®) in Korea. The plan is to manufacture 80+ million doses of the ZyCoV-D vaccine, which
Read more
GOLDEN, Colo. — December 14, 2021 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that one of its pharmaceutical partners, Nykode Therapeutics (formerly Vaccibody) has begun a phase 1/2 clinical trial to specifically address emerging SARS-CoV-2 variants. The DNA-based vaccines will be delivered intramuscularly in the clinical
Read more
GOLDEN, Colo. — November 30, 2021 - PharmaJet®, the maker of innovative, needle-free injection technology, has been named “Asia’s Most Innovative Vaccine Delivery System” at the Asia-Pacific Vaccine Excellence Awards 2021 (AVEA 2021). The award was accepted by Paul LaBarre, MS, MBA, Vice President, Global Business Development, PharmaJet, Inc.
Read more
GOLDEN, Colo. — October 21, 2021 - PharmaJet® the maker of innovative, needle-free injection technology, today announced that its Tropis® intradermal needle-free injection system is being used in a campaign in Somalia delivering inactivated polio vaccine to more than 110,000 children. The purpose of the campaign, funded in part by
Tags: Polio, Tropis
Read more
GOLDEN, Colo. — September 14, 2021 - PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its partner, Scancell, has selected its devices to administer its two SARS-CoV-2 DNA vaccine candidates, SCOV1 and SCOV2. The vaccines will be exclusively administered using the PharmaJet Tropis® and PharmaJet Stratis® Needle-free
Read more
GOLDEN, Colo. — August 23, 2021 - PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its partner, Zydus Cadila has received the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D the world’s first Plasmid DNA Vaccine for COVID-19. The vaccine, ZyCoV-D,
Read more
GOLDEN, Colo. — July 7, 2021 - PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its partner Zydus Cadila has applied for Emergency Use Authorization (EUA) to the office of the Drug Controller General of India (DCGI) for its plasmid DNA Vaccine against COVID-19. The vaccine, ZyCoV-D,
Read more
GOLDEN, Colo. — June 30, 2021 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that patient enrollment has started for the phase 1 trial in Australia using its Needle-free Injection Systems to deliver a vaccine against SARS-CoV-2. COVIGEN, a DNA-based vaccine was developed by French-Thai pharmaceutical company
Read more
Menu